Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Synaffix B.V. United Kingdom United States of America Netherlands

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologiesView original content:https://www.prnewswire.co.uk/news-releases/elevation-oncology-licenses-adc-technology-from-synaffix-to-drive-pipeline-expansion-302329298.html